Monopar Q2 2026: Cash Runway Through 2027, Rolling NDA Submission Underway

summarizeSummary

Monopar's Q2 2026 net loss widened to $5.3M on higher R&D, while its $134.3M cash position provides runway through 2027 and the rolling NDA for ALXN1840 remains on track.

check_boxKey Events · Earnings and Guidance · MNPR

• Q2 Net Loss Widens on R&D

  Net loss of $5.3M ($0.62/share) vs $2.5M ($0.35/share) in Q2 2025, driven by a $3.0M increase in R&D expenses to $4.8M.

• Cash Runway Through 2027

  Cash, equivalents, and investments of $134.3M as of June 30, 2026, expected to fund operations through at least December 2027, including ALXN1840 regulatory and pre-commercial activities.

• Rolling NDA Submission Initiated

  Initiated rolling NDA submission for ALXN1840 on July 22, 2026; completion expected within the next few months. FDA granted Rare Pediatric Disease designation, making a Priority Review Voucher available upon approval.

• Commercial Build-Out Underway

  Chief Commercial and Strategy Officer Susan Rodriguez leading launch preparations; board and senior commercial hires announced.

auto_awesomeAnalysis · MNPR · Life Sciences

Monopar's Q2 results show a net loss of $5.3 million, up from $2.5 million a year ago, driven by a near-tripling of R&D spend as the company advances ALXN1840 toward an NDA. The $134.3 million cash position funds operations through at least December 2027, covering regulatory and pre-commercial activities. The rolling NDA submission, initiated in July, is the key value driver — approval would unlock a Priority Review Voucher and a first-in-class Wilson disease therapy. The concurrent 10-Q disclosure of six insiders adopting 10b5-1 plans adds a governance overhang, but the earnings update itself is a routine quarterly event with no major surprises.